Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
CA 2508348 C · Owner: Millennium Pharmaceuticals, Inc. · Inventors: Morrissey, Michael P.; Damokosh, Andrew I.; Bolt, Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular the , present invention is directed to the use of certain combinations of markers wherein the expression of the markers correlates with responsiveness or nonresponsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 2003 and granted July 12, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.